# Polaris Venture Capital

> Polaris Venture Capital is a VC fund in Tel Aviv backing Health Care and Biotechnology. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tel Aviv, Israel
- Total investments: 20
- Last investment: Dec 2024
- Lead investor: 10%
- Fund size: $500M
- Last fund: May 2000
- Last updated: Aug 2026
- Website: http://www.polarisvc.com

Polaris Venture Capital is a VC fund in Tel Aviv focused on Health Care and Biotechnology. Polaris Venture Capital is committed to building successful enterprises through value-added partnerships with promising technology companies. With the recent closing of Polaris Fund III, and the merger of the management team of Polaris with the Eucalyptus Ventures management team, Polaris Venture Capital is by far the largest and most experiencedventure capital management group originating in Israel. Possessing vast experience in equity investments and high-technology management, Polaris Venture Capital is now managing over $700 million.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 40% |
| Biotechnology | 8 | 40% |
| Internet | 3 | 15% |
| Therapeutics | 3 | 15% |
| Pharmaceutical | 3 | 15% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 30% |
| Series A | 3 | 15% |
| Seed | 2 | 10% |
| Funding Round | 2 | 10% |
| Pre-Seed | 1 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 75% |
| Israel | 2 | 10% |
| Germany | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Freckle | Freckle offers a data enrichment and research platform for non-technical users. | $1.9M | Pre-Seed | Dec 02, 2024 |  |
| Seraxis | Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic andprovide a long term cure to patients that does not require the use of immuno-suppression.Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders. | $40M | Series C | Feb 09, 2021 |  |
| NakedPoppy | NakedPoppy is a seed-stage clean beauty company that matches women with better-for-her makeup tailored to individual needs and preferences. The company's patent-pending personalization algorithm helps customers quickly find makeup that matches or complements their skin tone. It leverages technology and maintains a list of known or suspectedtoxins that are harmful to skin, and rigorously screens beauty products followed by their testing and vetting, thereby providing females with a range of natural makeup products for improved skin regimen. | $4.1M | Seed | Mar 27, 2019 |  |
| Lyra Therapeutics | Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently delivermedicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. | $29.5M | Series B | Sep 26, 2018 |  |
| Respicardia | Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing patternduring sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™. | $58.5M |  | Dec 19, 2017 |  |
| Cardlytics | Cardlytics uses purchase-based intelligence to make marketing more relevant and measurable. They partner with more than 1,500 financial institutions – including Bank of America and PNC – to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In turn, they have a secure view into where and whenconsumers are spending their money. They use these insights to help marketers identify, reach and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in London, New York, Chicago and San Francisco. | $11.9M | Series G | May 18, 2017 |  |
| aTyr Pharma | aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas ofinflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. | $76M | Series E | Mar 31, 2015 |  |
| Ocular Therapeutix | Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $23.8M | Series D | Jun 10, 2013 |  |
| Avitide | Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions.The company was founded in 2012 andis based in Lebanon, New Hampshire. | $1.4M | Series A | Mar 04, 2013 |  |
| Avila Therapeutics | Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7,2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation. | $30M | Series B | Jul 27, 2009 |  |

10 of 20 investments shown.

## Co-investors
- Venture Capital Fund of New England — VC Fund, 3 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Advent Venture Partners](https://shizune.co/investors/profile/advent-venture-partners) — VC Fund, 1 deal together
- Aimia — VC Fund, 1 deal together
- ArrowMark Partners — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Polaris Venture Capital invest in?

Polaris Venture Capital invests primarily in Health Care, Biotechnology and Internet startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Polaris Venture Capital last invest?

The most recent investment recorded for Polaris Venture Capital closed in Dec 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co